GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » AIM ImmunoTech Inc (STU:HXB2) » Definitions » Cyclically Adjusted PS Ratio

AIM ImmunoTech (STU:HXB2) Cyclically Adjusted PS Ratio : 1.44 (As of May. 23, 2024)


View and export this data going back to . Start your Free Trial

What is AIM ImmunoTech Cyclically Adjusted PS Ratio?

As of today (2024-05-23), AIM ImmunoTech's current share price is €0.36. AIM ImmunoTech's Cyclically Adjusted Revenue per Share for the quarter that ended in Mar. 2024 was €0.25. AIM ImmunoTech's Cyclically Adjusted PS Ratio for today is 1.44.

The historical rank and industry rank for AIM ImmunoTech's Cyclically Adjusted PS Ratio or its related term are showing as below:

STU:HXB2' s Cyclically Adjusted PS Ratio Range Over the Past 10 Years
Min: 0.75   Med: 15.47   Max: 49.98
Current: 1.54

During the past years, AIM ImmunoTech's highest Cyclically Adjusted PS Ratio was 49.98. The lowest was 0.75. And the median was 15.47.

STU:HXB2's Cyclically Adjusted PS Ratio is ranked better than
80.83% of 506 companies
in the Biotechnology industry
Industry Median: 5.665 vs STU:HXB2: 1.54

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.

AIM ImmunoTech's adjusted revenue per share data for the three months ended in Mar. 2024 was €0.001. Add all the adjusted revenue per share for the past 10 years together and divide 10 will get our Cyclically Adjusted Revenue per Share, which is €0.25 for the trailing ten years ended in Mar. 2024.

Shiller PE for Stocks: The True Measure of Stock Valuation


AIM ImmunoTech Cyclically Adjusted PS Ratio Historical Data

The historical data trend for AIM ImmunoTech's Cyclically Adjusted PS Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

AIM ImmunoTech Cyclically Adjusted PS Ratio Chart

AIM ImmunoTech Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cyclically Adjusted PS Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 1.05 3.91 2.18 0.89 1.50

AIM ImmunoTech Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Cyclically Adjusted PS Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1.28 2.07 1.46 1.50 1.76

Competitive Comparison of AIM ImmunoTech's Cyclically Adjusted PS Ratio

For the Biotechnology subindustry, AIM ImmunoTech's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


AIM ImmunoTech's Cyclically Adjusted PS Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, AIM ImmunoTech's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where AIM ImmunoTech's Cyclically Adjusted PS Ratio falls into.



AIM ImmunoTech Cyclically Adjusted PS Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PS Ratio takes the Revenue per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/S calculation. Because it considers this 10-year average, it's often referred to as the CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio.

AIM ImmunoTech's Cyclically Adjusted PS Ratio for today is calculated as

Cyclically Adjusted PS Ratio=Share Price/ Cyclically Adjusted Revenue per Share
=0.36/0.25
=1.44

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

AIM ImmunoTech's Cyclically Adjusted Revenue per Share for the quarter that ended in Mar. 2024 is calculated as:

For example, AIM ImmunoTech's adjusted Revenue per Share data for the three months ended in Mar. 2024 was:

Adj_RevenuePerShare=Revenue per Share/CPI of Mar. 2024 (Change)*Current CPI (Mar. 2024)
=0.001/131.7762*131.7762
=0.001

Current CPI (Mar. 2024) = 131.7762.

AIM ImmunoTech Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201406 0.074 100.560 0.097
201409 0.097 100.428 0.127
201412 0.084 99.070 0.112
201503 0.081 99.621 0.107
201506 0.094 100.684 0.123
201509 0.043 100.392 0.056
201512 0.053 99.792 0.070
201603 0.075 100.470 0.098
201606 0.028 101.688 0.036
201609 0.040 101.861 0.052
201612 0.027 101.863 0.035
201703 0.137 102.862 0.176
201706 0.306 103.349 0.390
201709 0.111 104.136 0.140
201712 0.058 104.011 0.073
201803 0.055 105.290 0.069
201806 0.028 106.317 0.035
201809 0.031 106.507 0.038
201812 0.191 105.998 0.237
201903 0.000 107.251 0.000
201906 0.014 108.070 0.017
201909 0.021 108.329 0.026
201912 0.004 108.420 0.005
202003 0.002 108.902 0.002
202006 0.001 108.767 0.001
202009 0.001 109.815 0.001
202012 0.001 109.897 0.001
202103 0.001 111.754 0.001
202106 0.000 114.631 0.000
202109 0.001 115.734 0.001
202112 0.001 117.630 0.001
202203 0.001 121.301 0.001
202206 0.001 125.017 0.001
202209 0.000 125.227 0.000
202212 0.001 125.222 0.001
202303 0.001 127.348 0.001
202306 0.001 128.729 0.001
202309 0.001 129.860 0.001
202312 0.001 129.419 0.001
202403 0.001 131.776 0.001

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


AIM ImmunoTech  (STU:HXB2) Cyclically Adjusted PS Ratio Explanation

Compared with the regular PS Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PS Ratio smoothed out the fluctuations of revenue during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PS Ratio should give similar results to regular PS Ratio.


AIM ImmunoTech Cyclically Adjusted PS Ratio Related Terms

Thank you for viewing the detailed overview of AIM ImmunoTech's Cyclically Adjusted PS Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


AIM ImmunoTech (STU:HXB2) Business Description

Traded in Other Exchanges
Address
2117 SW Highway 484, Ocala, FL, USA, 34473
AIM ImmunoTech Inc is an immuno-pharma company focused on research and development of therapeutics to treat immune disorders, viral and cancer diseases. AIM's flagship products include Ampligen (Rintatolimod), a drug of large macromolecular RNA molecules for cancer and viral diseases and drug Alferon N Injection for a category of STD infection. Clinical trials of Ampligen include studies of cancer patients with renal cell carcinoma, malignant melanoma, colorectal cancer, advanced recurrent ovarian cancer and triple negative metastatic breast cancer. The company is also advancing Ampligen as a potential treatment for COVID-19. FDA has authorized the first human trial assessing the safety and effectiveness of Ampligen in combination with interferon alfa-2b, in cancer patients with COVID-19.

AIM ImmunoTech (STU:HXB2) Headlines

No Headlines